These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7037872)

  • 1. The treatment of severe Raynaud's phenomenon with verapamil.
    Kinney EL; Nicholas GG; Gallo J; Pontoriero C; Zelis R
    J Clin Pharmacol; 1982 Jan; 22(1):74-6. PubMed ID: 7037872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Cardiol; 1985 Jan; 55(3):154B-157B. PubMed ID: 3881908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enalapril in Raynaud's phenomenon.
    Janini SD; Scott DG; Coppock JS; Bacon PA; Kendall MJ
    J Clin Pharm Ther; 1988 Apr; 13(2):145-50. PubMed ID: 2839529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Raynaud's phenomenon with calcium channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M
    Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.
    Rustin MH; Almond NE; Beacham JA; Brooks RJ; Jones DP; Cooke ED; Dowd PM
    Br J Dermatol; 1987 Dec; 117(6):751-8. PubMed ID: 3322358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists].
    Shcherbakov AB
    Vutr Boles; 1988; 27(6):55-8. PubMed ID: 3247706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prazosin treatment of primary Raynaud's phenomenon.
    Nielsen SL; Vitting K; Rasmussen K
    Eur J Clin Pharmacol; 1983; 24(3):421-3. PubMed ID: 6345178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud's phenomenon.
    Coppock JS; Hardman JM; Bacon PA; Woods KL; Kendall MJ
    Postgrad Med J; 1986 Jan; 62(723):15-8. PubMed ID: 3099273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.